TABLE 2.
Univariate and multivariable analyses of the determinants of length of in hospital stay and overall survival
| Length of in‐hospital stay | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariable analysis | Univariate analysis | Multivariable analysis b | |||||
| sHR (95% CI) | p value | sHR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Gender (male vs female) | 1.11 (0.70–1.76) | 0.665 | — | — | 1.47 (0.70–3.07) | 0.307 | — | — |
| Age ≥ 70 years | 2.49 (1.47–4.21) | 0.001 | 2.34 (1.32–4.17) | 0.004 | 4.73 (2.30–9.75) | <0.001 | 4.08 (1.94–8.57) | <0.001 |
| Comorbidities (≥1 vs 0) | 1.98 (1.24–3.14) | 0.004 | 1.50 (0.91–2.48) | 0.109 | 3.42 (1.32–8.85) | 0.011 | 2.50 (0.95–6.57) | 0.064 |
| Hypertension | 1.64 (1.01–2.66) | 0.044 | — | — | 2.34 (1.19–4.62) | 0.014 | — | — |
| Obesity (BMI ≥ 30 kg/m2) | 1.01 (0.97–1.06) | 0.546 | — | — | 1.02 (0.96–1.08) | 0.579 | — | — |
| Smoking status (vs never smoker) | ||||||||
| Former smoker | 1.45 (0.81–2.60) | 0.215 | — | — | 1.77 (0.85–3.66) | 0.126 | — | — |
| Current smoker | 0.76 (0.27–2.14) | 0.608 | — | — | 0.68 (0.09–5.15) | 0.709 | — | — |
| Histological subtype (vs B‐cell NHL) | ||||||||
| T‐cell lymphoma | 0.65 (0.28–1.51) | 0.318 | — | — | 0.71 (0.17–2.96) | 0.636 | — | — |
| Hodgkin lymphoma | 0.43 (0.20–0.90) | 0.024 | — | — | 0.28 (0.04–2.07) | 0.214 | — | — |
| Time from lymphoma diagnosis to admission for Covid‐19 (>12 months) | 1.00 (1.00–1.01) | 0.480 | — | — | 1.00 (1.00–1.01) | 0.455 | — | — |
| Lymphopenia (<1 G/L) c | 1.55 (0.96–2.51) | 0.071 | — | — | 2.67 (1.02–6.97) | 0.044 | — | — |
| Hypogammaglobulinemia (<4 g/L) d | 1.45 (0.67–3.13) | 0.339 | — | — | 1.30 (0.42–4.03) | 0.649 | — | — |
| Lymphoma treatment | ||||||||
| Anti‐CD20 monoclonal antibody a | 1.83 (1.16–2.89) | 0.009 | 2.26 (1.42–3.60) | <0.001 | 1.60 (0.78–3.29) | 0.198 | 2.17 (1.04–4.52) | 0.039 |
| Bendamustine a | 3.37 (1.06–10.73) | 0.039 | — | — | 3.26 (1.42–7.52) | 0.006 | — | — |
| Any lymphoma therapy a | 1.45 (0.89–2.37) | 0.140 | — | — | 1.27 (0.58–2.81) | 0.55 | — | — |
| Relapsed/refractory lymphoma | 3.64 (1.32–9.98) | 0.012 | 3.12 (1.13–8.61) | 0.028 | 3.43 (1.63–7.18) | 0.001 | 3.34 (1.58–7.06) | 0.002 |
Abbreviations: BMI, body mass index; CI, confidence interval; NHL, non‐Hodgkin lymphoma; sHR, sub‐distribution hazard ratio.
a
Treatment administrated within the previous 12 months before hospitalization for Covid‐19.
b
Performed with the subset of independent variables found associated with length of in‐hospital stay at the 0.1% level.
c
Missing data in six patients.
d
Missing data in 45 patients.